New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.

Abstract

Mounting evidence suggests that diabetes mellitus (DM) is associated with mild cognitive impairment (MCI), vascular dementia and Alzheimer's disease (AD). Biological, clinical and epidemiological data support a close link between DM and AD. Increasingly, studies have found that several antidiabetic agents can promote neurogenesis, and clinically ameliorate cognitive and memory impairments in different clinical settings. Data has shown that these antidiabetic drugs positively affect mitochondrial and synaptic function, neuroinflammation, and brain metabolism. Evidence to date strongly suggests that these antidiabetic drugs could be developed as disease-modifying therapies for MCI and AD in patients with and without diabetes.

• Authors: Kai Long Zhong, Fang Chen, Hao Hong, Xuan Ke, Yang Ge Lv, Su Su Tang, Yu Bing Zhu
• Journal: Metabolic brain disease (Metab Brain Dis) Vol. 33 Issue 4 Pg. 1009-1018 (08 2018) ISSN: 1573-7365 [Electronic] United States
• PMID: 29626315 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Hypoglycemic Agents

Topics

• Alzheimer Disease (drug therapy, prevention & control)
• Cognitive Dysfunction (drug therapy, prevention & control)
• Humans
• Hypoglycemic Agents (therapeutic use)